Britain is squeezing AstraZeneca too tight
NHS curbs on drug prices have alienated UK pharma companies and become self-defeating
Related reading
US urged UK to offer better drug pricing deal to pharma companies
Ambassador’s meeting with chancellor Rachel Reeves came days before AstraZeneca and Merck paused projects in Britain
Europe is risking ‘health sovereignty’ by underpaying for drugs, says…
CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs
Resumption of £300mn in UK projects is a result of trade deal with US that aims to increase medicines spending
Big Pharma is falling out of love with Britain
Life sciences should be a natural place to look for growth
UK urges pharma companies to invest after reaching drug pricing deal with US
Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs
AstraZeneca bounces back from scandal in China
Pharma group has installed new leadership in the country and pledged $2.5bn for a Beijing R&D centre